VCM
MLTX icon

Voleon Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Voleon Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.39M Sell
173,909
-199,112
-53% -$3.61M 0.06% 271
2026
Q1 		$6.95M Sell
373,021
-126,078
-25% -$2.09M 0.15% 148
2025
Q4 		$6.58M Buy
499,099
+458,826
+1,139% +$5.41M 0.14% 161
2025
Q3 		$289K Buy
+40,273
New +$2.1M 0.01% 730

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Voleon Capital Management's MLTX Position: Q2 2026 in Review

Voleon Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 53% in Q2 2026, selling an estimated $3.61M and leaving 173,909 shares worth $3.39M. The position accounts for 0.06% of the portfolio, ranked #271.

Voleon Capital Management first reported a position in MLTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $6.95M in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Voleon Capital Management held 173,909 shares of MoonLake Immunotherapeutics worth $3.39M as of Q2 2026.
  • Voleon Capital Management sold 199,112 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $3.61M.
  • MoonLake Immunotherapeutics made up 0.06% of Voleon Capital Management's portfolio in Q2 2026, its #271 holding.
  • Voleon Capital Management first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • Voleon Capital Management's MoonLake Immunotherapeutics position peaked at $6.95M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.